[Pharmacological characteristics of ARB and potential strategy to develop novel ARB].
Six AT1 receptor blockers (ARBs) are clinically available in Japan. There seems to be some difference among 6 ARBs in terms of basic and clinical pharmacological characteristics. However, the clinical significance of the difference among 6 ARBs in pharmacological characteristics remains to be fully determined. The combination of ARB with pioglitazone or statin seems to be more effective for treatment of cardiovascular diseases than either monotherapy, through more attenuation of tissue oxidative stress, indicating the clinical usefulness of these combination therapies. In this review, the potential strategy to develop novel ARBs is discussed.
Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences.
Shokei
S
Kim-Mitsuyama
D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000494:pharmacology; D019808:Losartan / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology
D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D019808:Losartan; C077793:candesartan cilexetil